Announcements Trials
Browse Landscape

Phase

Phase 2 45Phase 1/2 7Phase NA 4Phase 3 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 2Myelodysplastic Syndromes 1Leukemia, Myeloid 1Graft vs Host Disease 1

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Has results × thymoglobulin × Clear all
NCT01471444 2021-12-16

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

M.D. Anderson Cancer Center

Phase 3 Completed
256 enrolled 13 charts
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00568633 2019-09-24

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Stanford University

Phase 3 Terminated
58 enrolled 18 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡